Every 10-Q that Mirum Pharmaceuticals (MIRM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MIRM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRM filings page.
Mirum Pharmaceuticals reported strong top-line growth but a much larger loss for the quarter ended June 30, 2026. Product sales, net were $176.2 million for the quarter and $336.1 million for the first half of 2026, compared with $127.8 million and $239.4 million a year earlier.
Loss from operations reached $42.5 million for the quarter and $832.0 million for the first half, driven primarily by $742.7 million of acquired in-process research and development expenses related to the January 2026 Bluejay acquisition and a $16.4 million charge for the Incyte zilurgisertib license. Net loss was $67.2 million for the quarter and $857.4 million year-to-date, or $1.06 and $14.03 per share, respectively.
As of June 30, 2026, Mirum had total assets of $1.04 billion, including $561.3 million of unrestricted cash, cash equivalents and investments, and stated this provides sufficient capital to fund operations for at least twelve months. The company issued $690.0 million of 0.00% convertible senior notes due 2032 and exchanged or repurchased $237.2 million of its 4.00% 2029 notes, leaving $79.0 million principal outstanding. Shares outstanding increased to 64.8 million at June 30, 2026, and stockholders’ equity moved to a deficit of $10.4 million due to the expanded accumulated deficit.
Mirum Pharmaceuticals grew Q1 2026 product sales to $159.9 million, up from $111.6 million a year earlier, driven by Livmarli and its bile acid medicines. Despite this growth, Mirum reported a net loss of $790.2 million, largely from a one-time $726.3 million acquired in-process R&D charge tied to its Bluejay Therapeutics acquisition and related stock-based compensation.
Mirum closed the Bluejay deal for brelovitug, a late-stage hepatitis D candidate, with total consideration of about $771.1 million, and raised $259.9 million through a private placement of common stock and pre-funded warrants. Unrestricted cash, cash equivalents and investments were $420.6 million as of March 31, 2026, and the company believes this will fund operations for at least twelve months while it advances late-stage programs in PSC, PBC, HDV and other rare diseases.
Mirum Pharmaceuticals (MIRM) reported strong Q3 2025 results. Product sales, net reached $133,010 thousand, up from $90,302 thousand a year ago, driven by Livmarli at $92,235 thousand and Bile Acid Medicines at $40,775 thousand. The company posted net income of $2,905 thousand, or $0.05 diluted EPS, versus a loss last year.
Cash and cash equivalents were $282,021 thousand, with unrestricted cash, cash equivalents and investments of $378.0 million as of September 30, 2025. Year‑to‑date operating cash flow was $49,760 thousand. Stockholders’ equity rose to $292,046 thousand from $225,640 thousand at year‑end. Principal on the 4.00% Convertible Senior Notes due 2029 was $316,233 thousand; the notes met conversion conditions in Q3 and Q4 2025, and conversions to date were not material. Total U.S. product sales were $103,713 thousand, with $29,297 thousand from the rest of the world. Common shares outstanding were 51,393,574 as of October 31, 2025.